Two cases of vancomycin-intermediate staphylococcus aureus isolated from joint tissue or wound

Korean Journal of Laboratory Medicine

Volumn 28, Issue 6, 2008, Pages 444-448

  Hong, Ki Ho ^a   Park, Jeong Su ^a   Kim, Eui Chong ^a  

^a Seoul National University   (South Korea)

Author keywords

Korea; Vancomycin intermediate staphylococcus aureus; Visa

Indexed keywords

ANTIINFECTIVE AGENT; MEROPENEM; THIENAMYCIN DERIVATIVE; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; ARTICLE; CASE REPORT; DECUBITUS; HUMAN; ISOLATION AND PURIFICATION; JOINT; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; STAPHYLOCOCCUS INFECTION;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; HUMANS; JOINTS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PRESSURE ULCER; STAPHYLOCOCCAL INFECTIONS; THIENAMYCINS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 62349140589     PISSN: 15986535     EISSN: None     Source Type: Journal    
DOI: 10.3343/kjlm.2008.28.6.444     Document Type: Article

References (14)

1. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. Highdose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006;166: 2138-44. (Pubitemid 44631403)
2. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Sixteenth Informational Supplement, M100-S16. Wayne, PA: Clinical and Laboratory Standards Institute, 2006.
3. Kim MN, Pai CH, Woo JH, Ryu JS, Hiramatsu K. Vancomycin-intermediate Staphylococcus aureus in Korea. J Clin Microbiol 2000;38: 3879-81.
4. Kim HB, Lee YS, Kim BS, Cha JO, Kwon SU, Lee HJ, et al. Prevalence and clinical implications of Staphylococcus aureus with a vancomycin MIC of 4 microg/ml in Korea. Microb Drug Resist 2006; 12:33-8.
5. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard-Seventh Edition, M7-A7. Wayne, PA: Clinical and Laboratory Standards Institute, 2006.
6. Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes FP, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003; 348:1342-7. (Pubitemid 36384101)
7. Neugen M, Pettyjohn R, Sahm DF. Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA). http://www.narsa.net/(Updated on Jul 2008).
8. Appelbaum PC. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin Microbiol Infect 2006;12(S):S16-23.
9. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 2001;1:147-55. (Pubitemid 33586048)
10. Gemmell CG, Edwards DI, Fraise AP, Gould FK, Ridgway GL, Warren RE. Guidelines for the prophylaxis and treatment of methicillinresistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 2006;57:589-608.
11. Drew RH. Emerging options for treatment of invasive, multidrugresistant Staphylococcus aureus infections. Pharmacotherapy 2007; 27:227-49. (Pubitemid 46214584)
12. Ruef C. Epidemiology and clinical impact of glycopeptide resistance in Staphylococcus aureus. Infection 2004;32:315-27. (Pubitemid 40104674)
13. Centers for Disease Conrol and Prevention. http://www.cdc.gov/ncidod/ dhqp/ar-visavrsa-labFAQ.htmL (Updated on Apr 2006).
14. Tenover FC, Lancaster MV, Hill BC, Steward CD, Stocker SA, Hancock GA, et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998;36:1020-7. (Pubitemid 28146289)